Gunderson Dettmer advised Remix Therapeutics on the deal.Remix Therapeutics, a Massachusetts-based biotech company, announced its $70 million Series B financing which included participation from Surveyor, Foresite Capital,…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Martina Bellini
…
This content is for Standard 1 Year members only. LoginJoin Now